Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Table 1

Percentage of common (>5%) cutaneous adverse events with vemurafenib treatment.

Adverse events	Percentage (%)
Verrucous papilloma/wart	22.2 [14]–79 [17]
Rash	64–71 [11]
Photosensitivity	22.2 [14]–66.7 [18]
Hand-foot skin reaction (PPD)	5.6 [14]–60 [17]
Hair growth modification	45 [17]
Actinic keratosis	40 [18]–44.4 [14]
Alopecia	11.1 [14]–36 [6]
Pruritus	29 [6]–33.3 [14]
Xerosis	11.1 [14]–33 [17]
Milia	26.7 [18]–31 [17]
cSCC and KA	22.2 [14]–26.7 [18]
Panniculitis	14 [17]–16.7 [14]
Keratosis pilaris	16.7 [14]
Cheilitis	14 [17]
BCC	13.3 [18]
Nipple hyperkeratosis	12 [17]
Nevi changes	5.6 [14]–10 [17]

PPD: palmar-plantar dysesthesia; cSCC: cutaneous squamous cell carcinoma; KA: keratoacanthoma; BCC: basal cell carcinoma.
In various studies, rash was categorised as erythema, maculopapular rash, folliculitis, and not otherwise specified; however some authors pointed out rash as a general term.
Indicated numbers beside the percentages denote the related references.